Alerts will be sent to your verified email
Verify EmailEMCURE
Emcure Pharma
|
JB Chem & Pharma
|
Piramal Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Domestic Sales Growth - YoY
|
7.3 % | 10.1 % | 15.43 % |
US DMF Filings
|
102.0 . | n/a | n/a |
R&D as a % of Total Sales
|
3.9 % | 1.35 % | 0.14 % |
Financials
|
|||
5 yr Average ROE
|
20.81 % | 19.49 % | 3.82 % |
5yr average Equity Multiplier
|
2.6 | 1.52 | 1.94 |
5yr Average Asset Turnover Ratio
|
0.93 | 0.77 | 0.55 |
5yr Avg Net Profit Margin
|
8.56 % | 16.71 % | 3.51 % |
Price to Book
|
6.2 | 7.82 | 3.11 |
P/E
|
37.04 | 39.17 | 257.53 |
5yr Avg Cash Conversion Cycle
|
-8.5 Days | 7.58 Days | -19.3 Days |
Inventory Days
|
82.11 Days | 50.33 Days | 70.13 Days |
Days Receivable
|
87.83 Days | 67.54 Days | 77.05 Days |
Days Payable
|
177.06 Days | 90.39 Days | 159.9 Days |
5yr Average Interest Coverage Ratio
|
5.19 | 58.81 | 2.86 |
5yr Avg ROCE
|
27.53 % | 23.05 % | 6.75 % |
5yr Avg Operating Profit Margin
|
19.97 % | 24.73 % | 15.15 % |
5 yr average Debt to Equity
|
0.76 | 0.07 | 0.62 |
5yr CAGR Net Profit
|
11.68 % | 8.05 % | -35.79 % |
5yr Average Return on Assets
|
7.99 % | 12.98 % | 2.03 % |
Shareholdings
|
|||
Promoter Holding
|
77.91 % | 47.73 % | 34.86 % |
Share Pledged by Promoters
|
0.04 % | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-0.17 % | -6.27 % | 0.07 % |
Change in Mutual Fund Holding (3 Yrs)
|
-0.96 % | 1.15 % | 11.78 % |
Emcure Pharma
|
JB Chem & Pharma
|
Piramal Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
-
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Acute vs Chronic
|
Acute vs Chronic
|
-
|
-
|
Asset Break-Up - Geography Wise
|
Asset Break-Up - Geography Wise
|
-
|
-
|